Securities code: 002907 securities abbreviation: Chongqing Pharscin Pharmaceutical Co.Ltd(002907) Announcement No.: 2022-001
Bond Code: 128069 bond abbreviation: Watson convertible bond
Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Description of abnormal fluctuations in stock trading
Chongqing Pharscin Pharmaceutical Co.Ltd(002907) (hereinafter referred to as “the company”) stock (Securities abbreviation: Huasen system)
Yao, securities code: 002907) was registered for three consecutive years on December 29, December 30 and December 31, 2021
Within a trading day, the deviation of the closing price increase from the value has exceeded 20%. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to abnormal fluctuations in stock trading.
2、 Attention to important issues and description of verification
In view of the abnormal fluctuation of the company’s stock trading, the board of directors of the company checked the company, the controlling shareholder and the actual controller on relevant matters. The relevant information is described as follows:
(i) The information disclosed by the company in the early stage does not need to be changed or supplemented.
（2） The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
（3） The disclosed business situation and internal and external business environment of the company have not changed significantly.
（4） After verification, the company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage.
（5） After verification, the controlling shareholder and actual controller did not buy or sell the company’s shares during the fluctuation period of stock trading.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any stock listing regulations of Shenzhen Stock Exchange at present
Matters that should be disclosed but not disclosed in accordance with the relevant provisions of the contract, or planning, negotiation, intention, agreement, etc. related to the matter; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by listed companies
(i) Through self-examination, the company does not violate the fair disclosure of information.
（2） The company reminds investors to pay special attention to the following risks: see Section III “management discussion and analysis” and part X “risks and Countermeasures Faced by the company” of the company’s 2021 semi annual report disclosed on August 18, 2021.
（3） Securities times, Securities Daily, China Securities News, Shanghai Securities News and cninfo（ http://www.cn.info.com..cn. ）For the information disclosure media selected by the company, all information of the company shall be subject to the information published in the above selected media. Investors are invited to invest rationally and pay attention to risks. It is hereby announced.
Chongqing Pharscin Pharmaceutical Co.Ltd(002907)
Board of directors
December 31, 2021
